The Pharmasyntez Group of Companies took another part in the "XI Baikal Forum against HIV infection. Synergy of science and practice. Interdisciplinary Aspects", which was held in Irkutsk on August 24 and 25.

The Forum brought together key experts in the field of HIV therapy, clinicians, researchers, and representatives of non-profit organizations.

The Pharmasyntez Group presented at the Forum new anti-HIV medications, including Raltegra (INN Raltegravir), Ravertir (INN Etravirine), and others.

There are currently more than 30 manufacturers of ARV drugs on the Russian market. 

In terms of physical production, Pharmasyntez is among the top domestic and international manufacturers. Every second package of ARV drugs in Russia is produced at Pharmasyntez's site.

Statistics, however, are unavoidable: HIV is one of the biggest global public health issues today. 

There were 39 million HIV-positive persons worldwide as of the end of 2022.

Over 40 million individuals have died from HIV-related causes, 630,000 have perished, and 1.3 million new cases have been reported alone in 2022. 

Around the world, 4,000 people are diagnosed with HIV every day; 1,100 of them are young people between the ages of 15 and 24.

Russia's percentage of the global disease incidence in 2021 was estimated to be around 4% by UNAIDS and the European Center for Disease Prevention and Control, coming in fourth place to South Africa (14%), Mozambique (6.5%), Nigeria (4.9%), and India (4.2%).

Although there is no definitive treatment for HIV infection, it has moved into the category of controlled diseases, allowing those who are infected to live long and generally healthy lives as a result of the development of antiretroviral therapy, increased access, and improved diagnostics.